Discussions in Cardiothoracic Treatment and Care: What the Surgeon Needs to Know About Checkpoint Inhibition in Immunotherapy

Semin Thorac Cardiovasc Surg. 2020;32(2):327-336. doi: 10.1053/j.semtcvs.2019.12.009. Epub 2019 Dec 30.
No abstract available

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Chemotherapy, Adjuvant
  • Clinical Decision-Making
  • Humans
  • Immunotherapy* / adverse effects
  • Neoadjuvant Therapy* / adverse effects
  • Neoplasm Staging
  • Patient Selection
  • Risk Factors
  • Thoracic Neoplasms / drug therapy*
  • Thoracic Neoplasms / immunology
  • Thoracic Neoplasms / pathology
  • Thoracic Neoplasms / surgery
  • Thoracic Surgical Procedures* / adverse effects
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological